Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Filgotinib (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions; Registrational
- Acronyms MANTA
- Sponsors Galapagos NV; Gilead Sciences
- 02 Dec 2023 This trial has been completed in Germany (Date of the global end of the trial: 24-Oct-2023), according to the European Clinical Trials Database record.
- 16 Nov 2023 Status changed from active, no longer recruiting to early termination for reasons other than safety .
- 14 Nov 2023 This trial has been discontinued in Spain, Belgium and Netherlands, according to European Clinical Trials Database record.